Research programme: papulopustular rosacea therapeutics - Attillaps Pharmaceuticals
Latest Information Update: 07 Oct 2021
At a glance
- Originator Attillaps Pharmaceuticals
- Class Anti-inflammatories; Skin disorder therapies; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Rosacea
Most Recent Events
- 01 Oct 2021 Preclinical trials in Rosacea in USA (Topical) prior to October 2021 (Attillaps Pharmaceuticals pipeline, October 2021)
- 29 Jun 2021 Attillaps Pharmaceuticals has patent protection for acetylcholinesterase inhibitors for treatment of dermatological conditions in USA, Australia, South Africa
- 29 Jun 2021 Attillaps Pharmaceuticals has patents pending for acetylcholinesterase inhibitors for treatment of dermatological conditions in European Union and Canada